AlphaQuest LLC Purchases 15,769 Shares of Collegium Pharmaceutical, Inc. $COLL

AlphaQuest LLC increased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 170.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,003 shares of the specialty pharmaceutical company’s stock after buying an additional 15,769 shares during the quarter. AlphaQuest LLC owned 0.08% of Collegium Pharmaceutical worth $875,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Federated Hermes Inc. grew its holdings in Collegium Pharmaceutical by 67.0% in the 3rd quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 350 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Collegium Pharmaceutical by 1.4% during the second quarter. Franklin Resources Inc. now owns 29,172 shares of the specialty pharmaceutical company’s stock valued at $863,000 after acquiring an additional 409 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Collegium Pharmaceutical by 0.6% during the second quarter. Legal & General Group Plc now owns 89,829 shares of the specialty pharmaceutical company’s stock worth $2,656,000 after purchasing an additional 531 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Collegium Pharmaceutical by 6.9% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,252 shares of the specialty pharmaceutical company’s stock worth $244,000 after purchasing an additional 534 shares during the last quarter. Finally, Sei Investments Co. increased its holdings in Collegium Pharmaceutical by 5.5% during the 2nd quarter. Sei Investments Co. now owns 11,436 shares of the specialty pharmaceutical company’s stock valued at $338,000 after purchasing an additional 600 shares during the period.

Insider Buying and Selling

In other news, Director Rita J. Balice-Gordon sold 3,650 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $47.03, for a total value of $171,659.50. Following the sale, the director directly owned 52,629 shares of the company’s stock, valued at $2,475,141.87. The trade was a 6.49% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Scott Dreyer sold 17,600 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $48.17, for a total value of $847,792.00. Following the transaction, the executive vice president directly owned 103,613 shares of the company’s stock, valued at approximately $4,991,038.21. This trade represents a 14.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 51,250 shares of company stock valued at $2,235,352 over the last quarter. Corporate insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Price Performance

Shares of COLL stock opened at $47.11 on Tuesday. The business’s fifty day moving average is $47.29 and its 200 day moving average is $40.31. The company has a quick ratio of 1.27, a current ratio of 1.36 and a debt-to-equity ratio of 2.71. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of 29.26 and a beta of 0.64. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, November 6th. The specialty pharmaceutical company reported $2.25 EPS for the quarter, beating the consensus estimate of $1.89 by $0.36. The business had revenue of $209.36 million during the quarter, compared to analyst estimates of $191.25 million. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%.The company’s revenue for the quarter was down 18.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.61 earnings per share. Research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on COLL shares. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective (up previously from $46.00) on shares of Collegium Pharmaceutical in a report on Friday, January 9th. Weiss Ratings restated a “buy (b-)” rating on shares of Collegium Pharmaceutical in a report on Monday, December 29th. Truist Financial set a $55.00 price target on Collegium Pharmaceutical in a research note on Wednesday, January 7th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $52.80.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.